Literature DB >> 28616588

All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS.

Adrian Vallejo1,2, Karmele Valencia1, Silvestre Vicent1,2,3.   

Abstract

KRAS proto-oncogene, GTPase (KRAS) remains refractory to current therapies. We devised an integrative cross-tumor approach to expose common core elements up-regulated in mutant KRAS cancers that could provide new treatment opportunities. This approach identified FOSL1 (Fos-like antigen 1) as a clinically and functionally relevant gene in mutant KRAS-driven lung and pancreatic cancers, and unveiled downstream transcriptional targets amenable to pharmacological inhibition.

Entities:  

Keywords:  FOSL1; KRAS oncogene; gene signature; lung cancer; mouse genetics; pancreatic cancer; pharmacological inhibitors

Year:  2017        PMID： 28616588      PMCID： PMC5462508          DOI： 10.1080/23723556.2017.1314239

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  Transformation by ras modifies AP1 composition and activity.

Authors:  F Mechta; D Lallemand; C M Pfarr; M Yaniv
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  FRA1 is a determinant for the difference in RAS-induced transformation between human and rat fibroblasts.

Authors:  Kyoko Kakumoto; Ken Sasai; Taiko Sukezane; Chitose Oneyama; Satoshi Ishimaru; Kana Shibutani; Hiroto Mizushima; Eisuke Mekada; Hidesaburo Hanafusa; Tsuyoshi Akagi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-28       Impact factor: 11.205

3.  miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Authors:  Ying Zhou; Jason Dang; Kung-Yen Chang; Edwin Yau; Pedro Aza-Blanc; Jorge Moscat; Tariq M Rana
Journal:  Cancer Res       Date:  2016-10-01       Impact factor: 12.701

Review 4.  Dragging ras back in the ring.

Authors:  Andrew G Stephen; Dominic Esposito; Rachel K Bagni; Frank McCormick
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

5.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility.

Authors:  Emmanuel Vial; Erik Sahai; Christopher J Marshall
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

6.  A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

Authors:  Ji Luo; Michael J Emanuele; Danan Li; Chad J Creighton; Michael R Schlabach; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582

Review 7.  RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Authors:  Julian Downward
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

8.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Authors:  Michael Steckel; Miriam Molina-Arcas; Britta Weigelt; Michaela Marani; Patricia H Warne; Hanna Kuznetsov; Gavin Kelly; Becky Saunders; Michael Howell; Julian Downward; David C Hancock
Journal:  Cell Res       Date:  2012-05-22       Impact factor: 25.617

9.  An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Authors:  Adrian Vallejo; Naiara Perurena; Elisabet Guruceaga; Pawel K Mazur; Susana Martinez-Canarias; Carolina Zandueta; Karmele Valencia; Andrea Arricibita; Dana Gwinn; Leanne C Sayles; Chen-Hua Chuang; Laura Guembe; Peter Bailey; David K Chang; Andrew Biankin; Mariano Ponz-Sarvise; Jesper B Andersen; Purvesh Khatri; Aline Bozec; E Alejandro Sweet-Cordero; Julien Sage; Fernando Lecanda; Silve Vicent
Journal:  Nat Commun       Date:  2017-02-21       Impact factor: 14.919
  9 in total
  3 in total

1.  ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis.

Authors:  Kun Peng; Ren-Peng Xia; Fan Zhao; Yong Xiao; Ti-Dong Ma; Ming Li; Yong Feng; Chong-Gao Zhou
Journal:  Mol Cell Biochem       Date:  2022-02-18       Impact factor: 3.396

2.  Gene signature for prognosis in comparison of pancreatic cancer patients with diabetes and non-diabetes.

Authors:  Mingjun Yang; Boni Song; Juxiang Liu; Zhitong Bing; Yonggang Wang; Linmiao Yu
Journal:  PeerJ       Date:  2020-11-11       Impact factor: 2.984

3.  Evolutionarily novel genes are expressed in transgenic fish tumors and their orthologs are involved in development of progressive traits in humans.

Authors:  E A Matyunina; A V Emelyanov; T V Kurbatova; A A Makashov; I V Mizgirev; A P Kozlov
Journal:  Infect Agent Cancer       Date:  2019-12-05       Impact factor: 2.965
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.